Amanda Ingham Adler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Amanda Ingham Adler has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Diana Bilton
Adult Cystic Fibrosis Clinic, Royal Brompton Hospital, London, U.K.
3 shared publicationsBrian S.F. Shine
John Radcliffe Hospital, Oxford, U.K.
2 shared publicationsCharles S. Haworth
Adult CF Centre, Papworth Hospital, Cambridge, U.K.
2 shared publications- Nita Gandhi Forouhi
University of Cambridge, Cambridge Biomedical Campus
2 shared publications - Parinya Chamnan
Cardiometabolic Research Group, Department of Social Medicine, Sunpasitthiprasong Regional Hospital, Ubon Ratchathani, Thailand
2 shared publications - Robert Luben
NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, England, UK
2 shared publications
Latest Publications
- 20 August 2019
- Published by Wiley in Diabetic Medicine
- Vol. 36 (11) , 1365-1366
To treat or not to treat: dysglycaemia in cystic fibrosis
- 20 August 2019
- Published by Wiley in Diabetic Medicine
- Vol. 36 (11) , 1365-1366
To treat or not to treat: dysglycaemia in cystic fibrosis
- Open Access
- 14 March 2019
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2019 (1)
Fatal squamous cell carcinoma from necrobiosis lipoidica diabeticorum in a diabetic patient
Summary: Necrobiosis lipoidica diabeticorum (NLD) is a chronic granulomatous dermatitis generally involving the anterior aspect of the shin, that arises in 0.3–1.2% of patients with diabetes mellitus (1). The lesions are often yellow or brown with telangiectatic plaque, a central area of atrophy and raised violaceous borders (2). Similar to other conditions with a high risk of scarring including burns, stasis ulcers and lupus vulgaris, NLD provides a favourable environment for squamous cell carcinoma (SCC) formation (3). A number of cases of SCC from NLD have been recorded (3, 4, 5); however, our search of the literature failed to identify any cases of either metastatic or fatal SCC which developed within an area of NLD. This article describes a patient with established type 1 diabetes mellitus who died from SCC which developed from an area of NLD present for over 10 years. Currently, there are a paucity of recommendations in the medical literature for screening people with NLD for the early diagnosis of SCC. We believe that clinicians should regard non-healing ulcers in the setting of NLD with a high index of clinical suspicion for SCC, and an early biopsy of such lesions should be recommended. Learning points: Non-healing, recalcitrant ulcers arising from necrobiosis lipoidica diabeticorum, which fail to heal by conservative measures, should be regarded with a high index of clinical suspicion for malignancy. If squamous cell carcinoma is suspected, a biopsy should be performed as soon as possible to prevent metastatic spread, amputation or even death. Our literature search failed to reveal specific recommendations for screening and follow-up of non-healing recalcitrant ulcers in the setting of necrobiosis lipoidica diabeticorum. Further research is required in this field.
- 14 March 2019
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2019 (1)
Open AccessFatal squamous cell carcinoma from necrobiosis lipoidica diabeticorum in a diabetic patient
Summary: Necrobiosis lipoidica diabeticorum (NLD) is a chronic granulomatous dermatitis generally involving the anterior aspect of the shin, that arises in 0.3–1.2% of patients with diabetes mellitus (1). The lesions are often yellow or brown with telangiectatic plaque, a central area of atrophy and raised violaceous borders (2). Similar to other conditions with a high risk of scarring including burns, stasis ulcers and lupus vulgaris, NLD provides a favourable environment for squamous cell carcinoma (SCC) formation (3). A number of cases of SCC from NLD have been recorded (3, 4, 5); however, our search of the literature failed to identify any cases of either metastatic or fatal SCC which developed within an area of NLD. This article describes a patient with established type 1 diabetes mellitus who died from SCC which developed from an area of NLD present for over 10 years. Currently, there are a paucity of recommendations in the medical literature for screening people with NLD for the early diagnosis of SCC. We believe that clinicians should regard non-healing ulcers in the setting of NLD with a high index of clinical suspicion for SCC, and an early biopsy of such lesions should be recommended. Learning points: Non-healing, recalcitrant ulcers arising from necrobiosis lipoidica diabeticorum, which fail to heal by conservative measures, should be regarded with a high index of clinical suspicion for malignancy. If squamous cell carcinoma is suspected, a biopsy should be performed as soon as possible to prevent metastatic spread, amputation or even death. Our literature search failed to reveal specific recommendations for screening and follow-up of non-healing recalcitrant ulcers in the setting of necrobiosis lipoidica diabeticorum. Further research is required in this field.
Incretins and cancer of the bile duct in type 2 diabetes
Existing trial data could help characterise this new association
Incretins and cancer of the bile duct in type 2 diabetes
Existing trial data could help characterise this new association
- Open Access
- 25 May 2018
- Published by Springer Nature in Cureus
- Vol. 10 (5) , e2690
Trichogranuloma in a Hairdresser with Systemic Sclerosis
Trichogranuloma is a rare occupational disease of hairdressers that develops when hair clippings penetrate the skin and cause a foreign-body reaction. We describe a case of a hairdresser with limited cutaneous systemic sclerosis who developed a chronic felon on her right third finger and received repeated courses of antibiotics without improvement. An occupational history and awareness of occupational diseases in hairdressers led to the correct diagnosis of trichogranuloma. Systemic sclerosis and concomitant finger ulcers may have predisposed the patient to this otherwise infrequent condition in an unusual location. Our case highlights the importance of occupational history and awareness of rare occupational diseases; we propose that treating and preventing skin disease may play a role in the prevention of trichogranuloma, thereby highlighting the need for protective measures in hairdressers.
- 25 May 2018
- Published by Springer Nature in Cureus
- Vol. 10 (5) , e2690
Open AccessTrichogranuloma in a Hairdresser with Systemic Sclerosis
Trichogranuloma is a rare occupational disease of hairdressers that develops when hair clippings penetrate the skin and cause a foreign-body reaction. We describe a case of a hairdresser with limited cutaneous systemic sclerosis who developed a chronic felon on her right third finger and received repeated courses of antibiotics without improvement. An occupational history and awareness of occupational diseases in hairdressers led to the correct diagnosis of trichogranuloma. Systemic sclerosis and concomitant finger ulcers may have predisposed the patient to this otherwise infrequent condition in an unusual location. Our case highlights the importance of occupational history and awareness of rare occupational diseases; we propose that treating and preventing skin disease may play a role in the prevention of trichogranuloma, thereby highlighting the need for protective measures in hairdressers.
- Open Access
- 16 November 2016
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 5 (1) , 7-8
Guilt, or guilt by association? Insulin therapy in type 2 diabetes and death
- 16 November 2016
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 5 (1) , 7-8
Open AccessGuilt, or guilt by association? Insulin therapy in type 2 diabetes and death
- Open Access
- 4 August 2016
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (12) , 1274-1278
Glucocorticoid‐induced hyperglycaemia in respiratory disease: a systematic review and meta‐analysis
The relative risk of glucocorticoid‐induced hyperglycaemia is poorly quantified. We undertook a meta‐analysis to estimate the association between glucocorticoid treatment and hyperglycaemia, overall and separately in individuals with and without diabetes and underlying respiratory disease. We searched electronic databases for clinical trials of adults randomized to either glucocorticoid treatment or placebo. Eight articles comprising 2121 participants were identified. We performed a random effects meta‐analysis to determine relative risks for the associations between glucocorticoid use and both hyperglycaemia and starting hypoglycaemic therapy. In all individuals, the relative risk of hyperglycaemia comparing glucocorticoid treatment with placebo was 1.72 [95% confidence interval ( CI ) 1.50‐2.04; p < .001]. The relative risks in individuals with and those without diabetes were 2.10 (95% CI 0.92‐5.02; p = .079) and 1.50 (95% CI 0.79‐2.86; p = .22), respectively. In all individuals, the relative risk of hyperglycaemia requiring initiation of hypoglycaemic therapy, comparing glucocorticoid treatment with placebo, was 1.73 (95% CI 1.40‐2.14; p < .001). In conclusion, glucocorticoid therapy increases the risk of hyperglycaemia in all individuals with underlying respiratory disease but not when diabetic status is analysed separately.
- 4 August 2016
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (12) , 1274-1278
Open AccessGlucocorticoid‐induced hyperglycaemia in respiratory disease: a systematic review and meta‐analysis
The relative risk of glucocorticoid‐induced hyperglycaemia is poorly quantified. We undertook a meta‐analysis to estimate the association between glucocorticoid treatment and hyperglycaemia, overall and separately in individuals with and without diabetes and underlying respiratory disease. We searched electronic databases for clinical trials of adults randomized to either glucocorticoid treatment or placebo. Eight articles comprising 2121 participants were identified. We performed a random effects meta‐analysis to determine relative risks for the associations between glucocorticoid use and both hyperglycaemia and starting hypoglycaemic therapy. In all individuals, the relative risk of hyperglycaemia comparing glucocorticoid treatment with placebo was 1.72 [95% confidence interval ( CI ) 1.50‐2.04; p < .001]. The relative risks in individuals with and those without diabetes were 2.10 (95% CI 0.92‐5.02; p = .079) and 1.50 (95% CI 0.79‐2.86; p = .22), respectively. In all individuals, the relative risk of hyperglycaemia requiring initiation of hypoglycaemic therapy, comparing glucocorticoid treatment with placebo, was 1.73 (95% CI 1.40‐2.14; p < .001). In conclusion, glucocorticoid therapy increases the risk of hyperglycaemia in all individuals with underlying respiratory disease but not when diabetic status is analysed separately.
- 10 August 2015
- Published by American Diabetes Association in Diabetes Care
- Vol. 38 (9) , 1634-1637
Trevor Orchard: Fruitful Contributions to Diabetes Epidemiology
- 10 August 2015
- Published by American Diabetes Association in Diabetes Care
- Vol. 38 (9) , 1634-1637
Trevor Orchard: Fruitful Contributions to Diabetes Epidemiology
- Open Access
- 10 April 2014
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (5) , 1304-1311
Association Between Glycemia and Mortality in Diabetic Individuals on Renal Replacement Therapy in the U.K.
OBJECTIVE: In the U.K., one-third of patients receiving treatment with dialysis have diabetes. Guidelines from organizations representing patients with renal disease or diabetes advocate tight glycemic control in patients with end-stage renal disease, despite glucose-lowering trials having excluded these patients. RESEARCH DESIGN AND METHODS: Using national UK Renal Registry data, we tested whether glycemia as measured by hemoglobin (Hb) A1c (HbA1c) level is associated with death in adults with diabetes starting hemodialysis or peritoneal dialysis between 1997 and 2006, and observed for at least 6 months. Of 7,814 patients, we excluded those who had died within 6 months; had received transplants; were lost/recovered; or lacked measures of HbA1c, ethnicity, or Hb. Categorizing HbA1c measured in the first 6 months of starting dialysis as 8.5% was 1 year. CONCLUSIONS: In the absence of trials, and confounding notwithstanding, these observational data support improved glycemic control in younger patients prior to and during dialysis.
- 10 April 2014
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (5) , 1304-1311
Open AccessAssociation Between Glycemia and Mortality in Diabetic Individuals on Renal Replacement Therapy in the U.K.
OBJECTIVE: In the U.K., one-third of patients receiving treatment with dialysis have diabetes. Guidelines from organizations representing patients with renal disease or diabetes advocate tight glycemic control in patients with end-stage renal disease, despite glucose-lowering trials having excluded these patients. RESEARCH DESIGN AND METHODS: Using national UK Renal Registry data, we tested whether glycemia as measured by hemoglobin (Hb) A1c (HbA1c) level is associated with death in adults with diabetes starting hemodialysis or peritoneal dialysis between 1997 and 2006, and observed for at least 6 months. Of 7,814 patients, we excluded those who had died within 6 months; had received transplants; were lost/recovered; or lacked measures of HbA1c, ethnicity, or Hb. Categorizing HbA1c measured in the first 6 months of starting dialysis as 8.5% was 1 year. CONCLUSIONS: In the absence of trials, and confounding notwithstanding, these observational data support improved glycemic control in younger patients prior to and during dialysis.
- 1 November 2013
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 1 (3) , 175-177
Drugs and diabetes: understanding the new breed of cardiovascular safety trials
- 1 November 2013
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 1 (3) , 175-177
Drugs and diabetes: understanding the new breed of cardiovascular safety trials
- 12 August 2012
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 14 (6) , 535-541
Recent Findings on the Effects of Marine-Derived n-3 Polyunsaturated Fatty Acids on Urinary Albumin Excretion and Renal Function
Albuminuria (this includes microalbuminuria and macroalbuminuria) and reduced glomerular filtration rate are present not only in high-risk populations, but also in the general population. These manifestations of renal disease are associated with an increased risk of cardiovascular disease and may reflect subclinical vascular disease. Long-chain n-3 polyunsaturated fatty acids have been vigorously studied for their potential cardioprotective effects. These fatty acids reduce the levels of serum lipids, blood pressure, inflammation, and endothelial dysfunction, all of which are associated with albuminuria and renal impairment; therefore, marine-derived n-3 fatty acids may potentially play a role in their prevention. This report reviews the recent findings relating marine-derived n-3 fatty acids to urinary albumin excretion and renal function and their risk factors. Although some evidence suggests that marine-derived n-3 fatty acids are associated with a lower incidence of albuminuria in diabetes, there is inadequate evidence supporting their role in glomerular filtration.
- 12 August 2012
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 14 (6) , 535-541
Recent Findings on the Effects of Marine-Derived n-3 Polyunsaturated Fatty Acids on Urinary Albumin Excretion and Renal Function
Albuminuria (this includes microalbuminuria and macroalbuminuria) and reduced glomerular filtration rate are present not only in high-risk populations, but also in the general population. These manifestations of renal disease are associated with an increased risk of cardiovascular disease and may reflect subclinical vascular disease. Long-chain n-3 polyunsaturated fatty acids have been vigorously studied for their potential cardioprotective effects. These fatty acids reduce the levels of serum lipids, blood pressure, inflammation, and endothelial dysfunction, all of which are associated with albuminuria and renal impairment; therefore, marine-derived n-3 fatty acids may potentially play a role in their prevention. This report reviews the recent findings relating marine-derived n-3 fatty acids to urinary albumin excretion and renal function and their risk factors. Although some evidence suggests that marine-derived n-3 fatty acids are associated with a lower incidence of albuminuria in diabetes, there is inadequate evidence supporting their role in glomerular filtration.